Highlightll announced that its proprietary, brain-penetrant NLRP3 inhibitor HL-400 has successfully completed the planned Single Ascending Dose (SAD) portion of its Phase I clinical study conducted in healthy volunteers in the United States.
Data from the SAD portion indicate that HL-400 was well tolerated with no dose-limiting toxicities (DLTs) observed. The compound demonstrated dose-proportional pharmacokinetics (PK) across the evaluated dose range. In addition, pharmacodynamic and biomarker assessments showed clear and robust inhibition of the NLRP3 inflammasome pathway, supporting the intended mechanism of action in humans.
The Multiple Ascending Dose (MAD) portion of the Phase Ⅰ study is currently ongoing, to be followed by a dedicated assessments of central nervous system (CNS) exposure for brain penetration.
Highlightll CEO, Dr. Chris Liang, commented that the preliminary clinical data is very encouraging, suggesting that HL-400 is a highly competitive brain penetrant NLRP3 inhibitor. Encouraged by this initial data, we are also advancing a peripheral NLRP3 inhibitor, HL-450, for peripheral diseases.
About Highlightll
Highlightll is a clinical stage biopharmaceutical company focusing on both peripheral and central autoimmune/inflammatory diseases. We strive to discover breakthrough medicines which would have a high impact on health care. We leverage resources and expertise worldwide and combine them with our unique perspectives to solve challenging medical problems. Our lead programs are the world's first highly potent and selective dual TYK2/JAK1 inhibitors. TLL-018, a peripheral TYK2/JAK1 inhibitor, is in Phase Ⅲ trials for chronic spontaneous urticaria (CSU) and rheumatoid arthritis (RA), while TLL-041, the world first brain-penetrant TYK2/JAK1 inhibitor was licensed to Biohaven in 2023. Biohaven advanced the BHV-8000/TLL-041 program to a global Phase II/III pivotal trial in Parkinson’s disease in May 2025. NLRP3 is our second platform where we are developing HL-400 for neurodegenerative diseases and HL-450 for peripheral diseases.
